Core Viewpoint - The development paths of medical beauty companies are diverging amid industry adjustments, with three leading companies—Hua Xi Bio, Juzi Bio, and Fulejia—reporting significantly different half-year results, reflecting a shift from "traffic dividends" to "technical barriers" in the industry [1] Group 1: Company Performance - Juzi Bio led with a revenue of 31.13 billion yuan and a year-on-year growth rate of 22.5% [4] - Hua Xi Bio reported a revenue of 22.61 billion yuan, a decline of 19.57% year-on-year, marking its worst interim report since listing [2][3] - Fulejia's revenue was 8.63 billion yuan, down 8.15% year-on-year, with a net profit drop of 32.54% [3][4] Group 2: Strategic Adjustments - Hua Xi Bio attributed its revenue decline to a drop in income from its skin science innovation transformation business, which saw a 33.97% decrease to 9.12 billion yuan [5][6] - Fulejia's revenue drop was linked to offline channel optimization, which increased sales expenses by 39.56% to 4.2 billion yuan [5][9] - Juzi Bio's growth was driven by the sales increase of professional skin care products, contributing 99.7% of its revenue [10][11] Group 3: Market Dynamics - The medical beauty industry is experiencing a shift, with the competition now focusing on research and development capabilities, patent layouts, and compliance [17] - The market for recombinant collagen products is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [15] - Hua Xi Bio is expanding into recombinant collagen while maintaining its position in hyaluronic acid, indicating a dual strategy to adapt to market changes [15][16]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 ...

Summary of Conference Call on Recombinant Collagen Industry Industry Overview - Recombinant collagen technology has gained popularity in the beauty and skincare industry due to its ability to reduce allergic reactions associated with animal-derived collagen and optimize production costs [1][2] - The industry has seen significant supply-side innovations since 2022, with advancements in gene engineering technology facilitating the commercial production of recombinant collagen [2] Key Companies Jinbo Biotechnology - Jinbo Biotechnology is a leading player in the recombinant collagen medical aesthetics sector, with revenue projected to grow from 160 million yuan in 2020 to 1.44 billion yuan in 2024, achieving a compound annual growth rate (CAGR) of over 70% [1][5] - The company's profit is expected to reach 730 million yuan in 2024, with a CAGR exceeding 100% [5] - Jinbo's new low-temperature gel filler product, approved in 2025, is anticipated to capture market share from animal-derived and regenerative materials [6] - The company plans to implement precise marketing strategies and product innovations to promote new products in the second half of the year [6] Juzhi Biotechnology - Juzhi Biotechnology has made significant strides in the functional skincare sector with products like the "collagen stick" and is expanding into niche markets such as scalp and intimate care [1][7] - The company benefits from national policy support, which has solidified its leading position in the industry [7] - Juzhi has transitioned to direct-to-consumer (DTC) online channels, enhancing sales performance through partnerships with top influencers on platforms like Tmall and Douyin [3][13] Jingbo Biotechnology - Jingbo has achieved progress in the research and certification of recombinant collagen products, accelerating its international market expansion [1][8] - The company has received certifications for functional skincare products in the U.S., Saudi Arabia, and Thailand, contributing to significant revenue growth [8] - Profit forecasts for Jingbo indicate 1.05 billion yuan in 2025 and 1.4 billion yuan in 2026, with a valuation of approximately 30 times earnings in 2025, decreasing to below 25 times in 2026 [9][10] Market Trends and Future Outlook - The acceptance of new products and materials by consumers is increasing, leading to the emergence of industry leaders like Jinbo and Juzhi in the medical aesthetics and functional skincare sectors [4] - The market for recombinant collagen is expected to grow as companies continue to innovate and expand their product offerings [6][7] - The focus on online sales channels and influencer marketing is driving growth in the skincare sector, with Juzhi's online sales showing exceptional performance [3][13] Important Considerations - Future performance indicators to watch include sales growth during the September and October periods, particularly around the Double Eleven shopping festival [16] - The approval of new medical aesthetic products will serve as a significant catalyst for growth, as current valuations primarily reflect cosmetics business performance [16][17] - Jinbo and Juzhi's advancements in recombinant collagen technology position them well for sustained growth in the evolving beauty and skincare market [18]

Summary of Giant Biogene Holding (2367.HK) Conference Call Company Overview - **Company**: Giant Biogene Holding (2367.HK) - **Industry**: Cosmetics and Skincare Key Points and Arguments Consumer Sentiment and Growth Outlook - Resilient consumer sentiment observed with 35-40% repeat purchases and 60% new consumer mix, indicating strong brand loyalty and market presence [1][3] - Management expressed confidence in achieving FY25 guidance, projecting sales growth of 25-28% year-over-year, targeting revenue between RMB6.9 billion and RMB7.1 billion [8][15] - Online growth expected to accelerate to approximately 30% year-over-year in the second half of FY25, with Double 11 sales anticipated to exceed this pace [3][14] Product Performance and New Launches - Luminous Facial Cream and Tier-2 product lines expected to outperform previous management expectations, while single-use essence may experience slower growth due to prior product content issues [3][9] - New SKUs under the Jiaodian series are set to launch in 1H26, targeting core consumer pain points in a fast-growing category [7][9] - Smaller brands like Keyu and SKIGIN projected to deliver strong performance, with Keyu generating over RMB100 million in sales last year [10][12] KOL (Key Opinion Leader) Strategy - Management noted a strong recovery in KOL promotions, with top KOLs like Austin Li and Sun Jian resuming product endorsements, which is expected to enhance brand visibility and sales [1][6][14] - KOLs have not reported negative feedback regarding product quality, indicating strong consumer trust [3][14] Offline Expansion and Channel Strategy - The company plans to increase its offline presence from 24 stores to over 30 by the end of 2025, with a focus on expanding sales through Sephora [7][12] - Positive feedback received for the Precise and Intensive Repair series, which is expected to contribute to incremental sales growth [12] Risk Factors and Market Position - Key risks include slower-than-expected growth, intensified competition in the skincare market, and potential regulatory challenges [13] - The company maintains a strong brand equity rooted in scientific innovation and a long-term commitment to functional skincare [2][13] Financial Metrics and Valuation - Target price set at HK$71, representing a potential upside of 31.8% from the current price of HK$53.85 [15] - Projected financials include revenue growth to RMB8.78 billion by FY26 and EBITDA growth to RMB3.33 billion by FY26 [15] Additional Important Insights - Management emphasized a disciplined approach to discounting during Double 11, aiming for stable pricing compared to previous shopping festivals [6][14] - The company is collaborating with Umer, a dermatology learning platform, to enhance medical-level endorsements for its products [14] This summary encapsulates the key takeaways from the conference call, highlighting the company's growth strategies, product performance, and market positioning within the cosmetics and skincare industry.

Core Viewpoint - The company demonstrated strong brand resilience and internal management capabilities, achieving significant growth in mid-term performance despite challenges faced in the second quarter [1][2]. Financial Performance - In the first half of the year, the company's revenue and net profit attributable to shareholders increased by 22.5% and 20.2% year-on-year, respectively [1]. - The gross margin and net profit margin remained high at approximately 82% and 38% [1]. Revenue Drivers - The main revenue growth drivers were online direct sales through e-commerce platforms (such as JD.com) and offline direct sales, which accounted for 75% of total revenue [1]. - Online direct sales to e-commerce platforms increased by 134%, while offline direct sales grew by 74% year-on-year [1]. Cost Management - The company effectively controlled sales expenses, with the sales expense ratio decreasing by 0.86 percentage points year-on-year, allowing for sufficient marketing investment in the second half of the year [2]. - The good control of sales expenses is attributed to the balanced development across various channels and the reduction in promotional activities due to the product issues in the second quarter [2]. Future Outlook - The company is expected to see a ramp-up in revenue in the second half of the year, driven by the recovery from short-term impacts, increased investment, and the launch of new products [2]. - Long-term focus on scientific research and commercialization in the collagen sector is recommended, with particular attention to upcoming sales during the Double Eleven shopping festival and the progress of medical device certifications [2]. Earnings Forecast - The earnings forecast for 2025-2027 has been slightly adjusted, with expected earnings per share of 2.33, 2.85, and 3.50 RMB, respectively [2]. - A target price of 81.46 HKD has been set for 2025, based on a 32x PE valuation [2].

Group 1 - The core viewpoint of the report is that Giant Bio's performance in the first half of the year slightly exceeded expectations, with total revenue reaching 3.113 billion yuan, representing a year-on-year growth of 22.5% [1] - Based on the strong performance in the first half and robust online sales in July, the company has raised its revenue forecast for the Comfy brand, adjusting total revenue projections for 2025 to 2027 upwards by 1.9% [1] - The earnings per share forecasts have been increased by 2%, 1.7%, and 1.7% for the years 2025, 2026, and 2027 respectively [1] Group 2 - The target price for the company has been slightly raised from 79 Hong Kong dollars to 79.5 Hong Kong dollars, maintaining a "buy" rating [1] - The report highlights a high visibility of growth in the restructuring of collagen products [1]

Industry Overview - The beauty industry is witnessing significant developments, including financial reports from various companies and the successful registration of new raw materials like Ursolic Acid [1] - Major brands are launching new products and entering new markets, indicating a dynamic and evolving landscape [1] Company Performance - Up Beauty reported a record revenue of 4.108 billion yuan for the first half of 2025, a year-on-year increase of 17.3%, with a net profit of 556 million yuan, up 34.7% [2] - Giant Biological achieved a revenue of 3.113 billion yuan in the first half of 2025, reflecting a 22.5% year-on-year growth, with a net profit of 1.182 billion yuan, up 20.6% [21] - Huaxi Biological reported a revenue of 2.261 billion yuan, with net profit figures showing no growth, but signs of strategic adjustments beginning to take effect [22] - Marubi Biological's revenue for the first half of 2025 reached 1.769 billion yuan, a 30.83% increase year-on-year, with a net profit of 186 million yuan, up 5.21% [23] New Product Developments - Up Beauty is preparing to launch a new makeup brand called "Dan Cai" in collaboration with a renowned makeup artist [2] - COSMAX announced breakthroughs in anti-aging and whitening products, including a new NAD-based anti-aging cosmetic and a new whitening powder [3] - LV Cosmetics has begun global pre-sales, indicating a strong push into the market [15] Executive Changes - Proya appointed new executives, including Xue Xia as the board secretary and Guo Xiao as the Chief Marketing Officer, both bringing extensive experience in the consumer sector [4] - Givaudan announced a leadership change, with Gilles Andrier stepping down as CEO in March 2026, to be succeeded by Christian Stammkoetter [5] Market Trends - The beauty and skincare market saw sales of 235.23 billion yuan in the first half of 2025, a 10.1% year-on-year increase, with anti-aging products showing a significant growth of 30.3% [24] - The introduction of innovative products and strategic partnerships, such as COSMAX's collaboration with Korea University for climate-proof cosmetics, reflects the industry's adaptability to changing consumer needs [15]

Core Viewpoint - The company reported strong revenue and profit growth in the first half of 2025, indicating robust performance across various product lines and channels [1][2]. Revenue Performance - In H1 2025, the company achieved revenue of 3.113 billion yuan, representing a year-on-year increase of 22.52% [1]. - Revenue breakdown by product category: - Efficacy skincare products: 2.410 billion yuan, accounting for 77.4%, with a growth of 24.2% - Medical dressings: 693 million yuan, accounting for 22.3%, with a growth of 17.1% - Health food and others: 10 million yuan, accounting for 0.3%, with a growth of 16.3% [1]. - Revenue breakdown by sales channel: - Direct sales: 2.325 billion yuan, accounting for 74.7%, with a growth of 26.5% - Distribution: 787 million yuan, accounting for 25.3%, with a growth of 12.1% [1]. Profitability Metrics - The company reported a gross margin of 81.68%, down by 0.72 percentage points, and a net profit margin of 37.98%, also down by 0.72 percentage points [2]. - The decline in gross margin was attributed to product category expansion, while supply chain cost optimization mitigated some of the downward trend [2]. Cost Management - The company's expense ratio decreased to 37.99%, down by 1.63 percentage points, with a sales expense ratio of 34.01%, down by 1.10 percentage points [2]. - R&D expense ratio decreased to 1.32%, down by 0.59 percentage points, due to the transition of some R&D projects to commercialization and reduced share-based compensation [2]. R&D and Product Development - The company is enhancing its R&D capabilities and expanding its product matrix, which is expected to support long-term growth [2]. - New product launches, such as the collagen stick 2.0 and collagen mask 3.0, have received positive consumer feedback, indicating strong product vitality [2]. Future Outlook - The company is expected to achieve revenues of 7.056 billion yuan, 8.790 billion yuan, and 10.568 billion yuan from 2025 to 2027, with net profits of 2.538 billion yuan, 3.189 billion yuan, and 3.867 billion yuan respectively [3]. - The company maintains a strong position in the collagen protein sector, with anticipated improvements in industry standing and penetration rates [3].

Core Insights - The company reported stable growth in its performance for the first half of 2025, achieving revenue of 3.113 billion with a year-on-year increase of 22.5% and a net profit attributable to shareholders of 1.182 billion, up 20.2% year-on-year [1] - The company maintains its full-year guidance, expecting a revenue growth rate of 25%-28% and a net profit of 2.5 billion to 2.55 billion, representing a year-on-year increase of 21%-24% [1] Brand Performance - The brand "可复美" generated revenue of 2.542 billion, a year-on-year increase of 22.7%, accounting for 81.7% of total revenue, with disposable products expected to represent 30% and dressings 25% of sales [1] - The brand "可丽金" achieved revenue of 503 million, up 26.9% year-on-year, although there was a slight decline in offline sales due to distributor impacts [1] Product Category Performance - Functional skincare products generated revenue of 2.410 billion, a year-on-year increase of 24.2%, while medical dressings brought in 693 million, up 17.0% year-on-year [1] - The growth in functional skincare revenue is attributed to refined operations across all channels, enhanced brand influence, and the successful launch of key products [1] Channel Performance - Direct sales channels generated revenue of 2.325 billion, a year-on-year increase of 26.5%, with online direct sales particularly strong at 391 million, up 133.6% due to targeted operations on e-commerce platforms [2] - Offline direct sales also saw significant growth, reaching 118 million, up 74.3%, driven by the accelerated layout of brand specialty stores [2] - The DTC store direct sales revenue was 1.816 billion, a year-on-year increase of 13.3%, while the distribution channel revenue was 787 million, up 12.1% [2] Profitability and Cost Structure - The company's gross margin and net margin for the first half of 2025 were 81.7% and 38.0%, respectively, reflecting a year-on-year decrease of 0.7 percentage points and 0.6 percentage points [2] - The decline in gross margin is primarily due to the increased proportion of lower-margin functional skincare products [2] - The sales, management, and R&D expense ratios were 34.0%, 2.7%, and 1.3%, showing a decrease in sales expense ratio due to refined operational management and changes in channel structure [2] Investment Outlook - The company shows a robust growth trend in its mid-year report, with core brands continuing to drive significant growth through the launch of new products and expansion in both online and offline channels [3] - The projected net profits for 2025-2027 are 2.549 billion, 3.092 billion, and 3.673 billion, corresponding to PE ratios of 20, 17, and 14 times, respectively, maintaining an "outperform" rating [3]

Core Viewpoint - The functional skincare industry in China is experiencing a rise of domestic brands, with various listed companies involved across the supply chain, including raw materials, packaging, and sales channels [1][2]. Group 1: Industry Overview - Functional skincare products are designed to address specific skin issues and possess certain pharmacological effects, indicating a growing market for targeted skincare solutions [1]. - The industry is characterized by a diverse range of companies, from raw material suppliers to online and offline sales channels [2]. Group 2: Company Distribution - Key companies in the raw materials segment include Kesheng Co., Qingsong Co., and Xinhang New Materials, while packaging material companies include Jiaheng Household and Jinsong New Materials [2][3]. - Major players in the functional skincare segment include Betaini, Huaxi Biological, Shanghai Jahwa, and Chuang'er Biological, with significant online sales channels represented by Alibaba, JD.com, and Pinduoduo [2][4]. Group 3: Financial Performance - Betaini leads the industry with a revenue of 57.36 billion yuan in 2024, followed by Huaxi Biological with 53.71 billion yuan and Shanghai Jahwa with 56.79 billion yuan [6][18]. - The gross profit margins for most companies in the functional skincare sector range from 70% to 85%, with Juzhi Biological achieving the highest margin at 82.09% [17][18]. Group 4: Business Strategies - Companies are focusing on R&D innovation, brand enhancement, and channel optimization to capture more market share and adapt to competitive pressures [19]. - Betaini plans to enhance its product offerings in the baby skincare segment and expand its online and offline presence, while Huaxi Biological is shifting towards anti-aging strategies and enhancing its technological capabilities [20][19]. Group 5: Market Positioning - Betaini has a dominant market position with 99.49% of its business in functional skincare, primarily targeting the Chinese market [16]. - Huaxi Biological and Shanghai Jahwa have also established strong brand identities with competitive product lines, while Chuang'er Biological focuses on collagen products [14][16].